Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy

Achilles Therapeutics

19/09/2024 12:40

Sept 19 (Reuters) - Achilles Therapeutics PLC  698y.F :
    * ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE
    * ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE
DEVELOPMENT
OF TIL-BASED CNET THERAPY
    * ACHILLES THERAPEUTICS PLC SAYS BOFA SECURITIES ENGAGED TO
PROVIDE STRATEGIC FINANCIAL ADVICE
    * ACHILLES THERAPEUTICS PLC: PROPOSING A WORKFORCE REDUCTION
    * ACHILLES THERAPEUTICS PLC SAYS  AS OF JUNE 30, 2024,
COMPANY HAD
$95.1 MILLION IN CASH AND CASH EQUIVALENTS
    * ACHILLES THERAPEUTICS: EXPLORING STRATEGIC ALTERNATIVES
MAY
INCLUDE ACQUISITION, MERGER, REVERSE MERGER, BUSINESS
COMBINATION, ASSET SALE, LICENSING
    * ACHILLES THERAPEUTICS PLC: TO EXPLORE ENGAGEMENT WITH
THIRD
PARTIES THAT DEVELOP ALTERNATIVE MODALITIES TO TARGET CLONAL
NEOANTIGENS
    * ACHILLES THERAPEUTICS PLC: INTENDS TO RETAIN ALL EMPLOYEES
ESSENTIAL FOR SUPPORTING VALUE-REALIZATION AS PART OF STRATEGIC
REVIEW

Source text for Eikon:  ID:nGNX71BZX0 
Further company coverage:  698y.F 

 ((Reuters.Briefs@thomsonreuters.com;))